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LETTER TO THE EDITOR
Alterations in bone marrow metabolism are an early and
consistent feature during the development of MGUS and
multiple myeloma
Blood Cancer Journal (2015) 5, e359; doi:10.1038/bcj.2015.85;
published online 16 October 2015
Multiple myeloma (MM) is a malignant disorder of plasma cells
arising from a clinically benign state known as monoclonal
gammopathy of undetermined signiﬁcance (MGUS). The biological
mechanisms for disease progression are not well understood.
As acquisition of malignant phenotypes by a tumour is often
associated with metabolic transformation, the cancer metabolome
may act as a dynamic read-out of its phenotype. The aim of this
investigation was therefore to characterise the metabolic proﬁle
within the bone marrow of healthy donors and patients with
MGUS or MM, and to determine if any observed differences
between these disorders could be observed within peripheral
plasma.
MM is a tumour of the bone marrow characterised by bone
destruction, anaemia, renal impairment and infection. It remains
incurable despite signiﬁcant improvements in therapy. MM is an
extremely heterogeneous disease both genetically and clinically
with variability in presentation, response to treatment, duration
of remissions and overall survival.1 However, it almost invariably
develops from the asymptomatic premalignant stage, MGUS.2
MGUS is common in the elderly but only a minority of MGUS indi-
viduals progress to develop symptomatic MM, with a frequency of
progression of around 1% per year. Interestingly, no speciﬁc
molecular changes have yet been identiﬁed as associated with the
progression of MGUS to MM: the genomic architecture of both
diseases being remarkably similar.3 The drivers that underlie the
development of MGUS and subsequent progression of patients to
malignant MM are therefore largely unknown. Because of the
large number of potential players within the bone marrow niche
in which the disease develops, it is possible that the driver may
not necessarily be the transformed plasma cell, but rather a
supporting cell type, or microenvironment. Metabolic proﬁling of
the niche in which MGUS and MM inhabits may therefore shed
light on the biological processes underpinning this disease.
However, there have been few studies characterising the
metabolic microenvironment of MM, and to our knowledge, none
on patients with MGUS. We therefore investigated the metabo-
lome of the bone marrow niche using ﬁltered plasma derived from
bone marrow aspirates of control, MGUS and MM patients by
1H-NMR spectroscopy (patient cohort information; Supplementary
Table 1, example annotated spectrum; Supplementary Figure 1a,
for methods; Supplementary Methods). Principal component
analysis (PCA) showed that the different patient groups could
be separated based on the metabolite peaks detected using two
components: PC1 and PC5 (Figure 1a and Supplementary
Methods). Importantly, PC1 alone, which contained over 50% of
the total variance in the sample, separated control samples from
MGUS and MM. In contrast, MGUS and MM were only separated in
PC5, which contained very little (2.7%) of the variance.
This suggested that the majority of changes in the metabolites
that we detected in the bone marrow of patients occur with the
development of MGUS and not with the progression to MM.
We therefore investigated those metabolic changes that were
associated with development of the disease. Of the metabolite
peaks that were identiﬁed, the essential amino acids, isoleucine
and threonine were found to be signiﬁcantly decreased in bone
marrow of MGUS and MM patients as were the nucleotide-
breakdown products, hypoxanthine and xanthine (Figure 1b).
As essential amino acids are only available from exogenous
sources, these changes suggest an increase in the anabolism of
the cells occupying the bone marrow in MGUS and MM, as would
be expected bearing in mind the proliferation of plasma cells in
this niche. In addition, excretion of both creatine and urea were
signiﬁcantly changed in this niche, with urea production increas-
ing over fourfold and creatine export decreasing over 16-fold
(Figure 1b). These metabolites are both products of arginine
metabolism in the urea cycle, suggesting that this pathway is
signiﬁcantly altered in the bone marrow of MGUS and MM
patients. Importantly, the signiﬁcant increase observed in urea in
MGUS patients is unlikely to be because of renal failure, as urine
creatinine levels were only elevated in a sub set of patients
(Supplementary Table 1). More work is needed to identify the
driver(s) of this change in metabolism and the cell type in which it
occurs. Interestingly, lactate concentrations did not signiﬁcantly
alter between any of the groups (Figure 1b). Lactate is considered
to be a marker of transformed metabolism, and indeed its
increased production in normoxia is the deﬁning feature of the
Warburg Effect. The absence of a signiﬁcant increase in lactate
concentrations may be owing to either efﬁcient excretion from the
bone marrow niche, or similarly to some normal tissues and solid
cancers a metabolic synergy between the different cell types
or microenvironments within the tumour that allows the lactate to
be metabolised.4–6
The metabolism of hypoxanthine to xanthine occurs in the
extracellular space, and metabolises molecular oxygen to form
hydrogen peroxide. As concentrations of both metabolites
changed in the MGUS and MM samples compared with control
(Figure 1b), we used the ratio of xanthine to hypoxanthine as a
correlate for the production of peroxide in the bone marrow
microenvironment. The increased ratio observed in MGUS and
MM samples suggested that this niche becomes more oxidative
with disease (Figure 1c). This more oxidative environment is likely
capable of eliciting new mutational events, and consistent with
the increased oxidative stress observed in patients with MM.7 Our
data suggest that this is also present in MGUS patients, and that
dysregulated bone marrow redox may be a unifying phenotype
that drives the development of paraproteinaemia.
As we were able to detect signiﬁcant alterations in metabolites
in the bone marrow microenvironment, we investigated whether
similar changes could be observed in the peripheral plasma
(patient cohort information: Supplementary Table 2). PCA analysis
of the 1H-NMR spectra derived from this bioﬂuid showed that
although the control group clustered, the MGUS and MM patient
samples demonstrated a much more heterogeneous pattern
(Figure 1d). In view of this, we chose metabolites for analysis that
we had previously identiﬁed as being altered in the bone marrow
(Supplementary Figure 1b). However, in the peripheral plasma,
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none of the previously identiﬁed metabolites detected were
signiﬁcantly altered, whereas creatine concentrations were too
low to be detected using this approach. We therefore subjected
peripheral plasma samples from the same cohort to metabolomic
analysis using the more sensitive ultra-high performance liquid
chromatography-mass spectrometry (Supplementary Methods).
PCA was again used to investigate whether the metabolites
identiﬁed were able to cluster the samples into their groups.
We found that control patients separated from MGUS and MM
patients in PC1 for the positively charged ion data set and in
PC2 for the negatively charged ion data set (Figures 2a and b),
with a greater separation in the former. For the positively charged
ion data set we also observed some partial separation of MM
patients from MGUS patients (Figure 2a), though this was not a
clear separation as observed for distinguishing control patients
from MGUS and MM patients, consistent with the results from the
bone marrow data set (Figure 1a). After statistical analysis, these
observations were reﬂected in the number of metabolites that
separated the groups, with over 200 putatively annotated
metabolites separating control from both MGUS and MM
(Supplementary Tables 3 and 4), and only 26 differentially
detected between MGUS and MM (Po0.005; Supplementary
Table 5). A number of metabolite classes were over-represented in
the putative metabolites identiﬁed that varied between control,
MGUS and MM samples (Figures 2c–f). As many of the classes are
associated with lipid metabolism, this suggests the dysregulation
of this area of metabolism may have a role in disease
pathogenesis or be useful as biomarkers, and that future studies
to investigate these pathways in the bone marrow, and speciﬁcally
plasma cells, of patients with MGUS and MM are likely to
be revealing.
We therefore show that MGUS and MM patients can be
differentiated from healthy individuals using both bone marrow
and peripheral plasma. In addition, we demonstrate that
the metabolites that were detected vary more between control
and ‘disease’ than between patients with MGUS and MM. This has
Figure 1. NMR spectroscopy proﬁling of the metabolome of the bone marrow niche of patients with MGUS and MM. (a) Unbiased multivariate
PCA of the 1H spectra demonstrated signiﬁcant separation of the bone marrow samples using two components: PC1 and PC5. PC1, which
separated control samples from both MGUS and MM contained almost 57% of the variation. In total, 10 samples from each group were
analysed. (b) Quantiﬁcation of the labelled metabolites through back-calculation of their concentrations that contributed to the loadings in
PC1 are shown. Data are represented by box and whisker plots with min–max whiskers. A non-parametric ANOVA (Kruskal–Wallis) test was
used to test for signiﬁcance, and where a signiﬁcant change was observed, a Dunn’s multiple comparisons post hoc test was performed. For
ANOVA, P= 0.0072 (isoleucine), 0.0043 (threonine), 0.0001 (hypoxanthine), 0.0001 (xanthine), o0.0001 (urea), o0.0001 (creatine). Where
shown: *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001 by Dunn’s multiple comparisons test. (c) Ratiometric analysis of xanthine/
hypoxanthine as a correlative measure of extracellular peroxide production in the bone marrow shows that it is increased with disease.
ANOVA (Kruskal–Wallis) test= 0.0003, Dunn’s multiple comparisons test performed, * values as shown above. (d) PCA analysis of the 1H spectra
acquired from peripheral plasma shows little separation between different patient groups.
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important implications for our understanding of this disease, as it
suggests that there is an early metabolic transformation of the
bone marrow microenvironment that may not be dependent on
signiﬁcant plasma cell occupancy, and that the progression of the
disease to MM requires changes to the metabolic phenotype that
are not necessarily visible in this niche. This hypothesis is also
supported by recent genetic studies that suggest that there are
few genetic changes associated with progression from MGUS to
MM.8
Metabolomic approaches can be used to identify biomarkers
and abnormal biological pathways in a number of diseases in a
wide range of contexts.9–13 However, as the metabolome can be
signiﬁcantly altered by factors such as gender, age and body mass
index, care must be taken through use of controlled cohorts and
unbiased analysis methods. There are currently very limited data
in MM patients with only a small number of publications to
date,11,13–16 although more studies have been performed using
myeloma cell lines. These studies have predominantly focused on
changes following therapy or changes in individual patients at
different time points in their disease, while this study is the ﬁrst to
compare global metabolites in MM, MGUS and healthy controls.
Our study, as well as those of others, suggests that peripheral
serum or plasma may well represent a means of determining
disease status for patients with MGUS and MM.14–16 In addition,
delineation of the characteristic metabolic abnormalities that
underlie the development of paraproteinaemia may reveal novel
opportunities for therapeutic intervention.
Figure 2. Mass spectrometry proﬁling of the peripheral plasma metabolome of patients with MGUS and MM. (a and b) PCA analysis of the
UHPLC-MS positive (a) and negative (b) ion mode data acquired from peripheral plasma shows separation of healthy controls from MGUS and
MM patients and no clear separation of MGUS patients from MM patients. (c) Overview of the metabolite classes that were signiﬁcantly altered
(cut-off Po0.005) in the peripheral plasma with respect to control samples. (d) Quantiﬁcation of the relative change in each metabolite class
in MGUS compared with healthy controls. Box and whisker plots show Tukey’s Whiskers with outliers marked. (e) Quantiﬁcation of the relative
change in each metabolite class in MM compared with healthy controls. (f) Quantiﬁcation of the relative change in each metabolite class in
MM compared with MGUS samples. Abbreviation: TCA, tricarboxylic acid.
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